Explore

Trendline Trendline
GeoVax Labs Reports Q2 Loss and Advances Vaccine Study

GeoVax Labs Reports Q2 Loss and Advances Vaccine Study

GeoVax Labs Reports Q2 Loss and Advances Vaccine Study
Trendline Trendline
Sarepta Therapeutics Names Michael Severino as CEO Amid Leadership Transition

Sarepta Therapeutics Names Michael Severino as CEO Amid Leadership Transition

Sarepta Therapeutics Names Michael Severino as CEO Amid Leadership Transition
Trendline Trendline
Tonix Pharmaceuticals to Announce Q2 2026 Financial Results Amid Expanding Treatment Portfolio

Tonix Pharmaceuticals to Announce Q2 2026 Financial Results Amid Expanding Treatment Portfolio

Tonix Pharmaceuticals to Announce Q2 2026 Financial Results Amid Expanding Treatment Portfolio
Trendline Trendline
Galderma Reports Strong Financial Growth in First Half of 2026

Galderma Reports Strong Financial Growth in First Half of 2026

Galderma Reports Strong Financial Growth in First Half of 2026
Trendline Trendline
Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences

Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences

Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences
Trendline Trendline
Calysta Seeks New Capital as Joint Venture Partner Ends Financial Support

Calysta Seeks New Capital as Joint Venture Partner Ends Financial Support

Calysta Seeks New Capital as Joint Venture Partner Ends Financial Support
Trendline Trendline
Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets
Trendline Trendline
GeoVax Labs Reports Q2 Financial Loss and Advances Vaccine Study

GeoVax Labs Reports Q2 Financial Loss and Advances Vaccine Study

GeoVax Labs Reports Q2 Financial Loss and Advances Vaccine Study
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases
Trendline Trendline
Devonian Health Group Plans NYSE American Listing with Public Offering

Devonian Health Group Plans NYSE American Listing with Public Offering

Devonian Health Group Plans NYSE American Listing with Public Offering
Trendline Trendline
Rosen Law Firm Urges GRAIL, Inc. Investors to Act Before August 4 Deadline in Securities Class Action

Rosen Law Firm Urges GRAIL, Inc. Investors to Act Before August 4 Deadline in Securities Class Action

Rosen Law Firm Urges GRAIL, Inc. Investors to Act Before August 4 Deadline in Securities Class Action
Trendline Trendline
Repligen Corporation Anticipates Steady Growth in Q2 Earnings Report

Repligen Corporation Anticipates Steady Growth in Q2 Earnings Report

Repligen Corporation Anticipates Steady Growth in Q2 Earnings Report